508 filings
Page 4 of 26
CORRESP
1f2xtnzq
27 Apr 23
Correspondence with SEC
12:00am
CORRESP
2r77nagvexke9 bxt2wp
27 Apr 23
Correspondence with SEC
12:00am
DEFA14A
5m2y 6c37t7xqx
26 Apr 23
Additional proxy soliciting materials
4:34pm
8-K
ns2lahzkc
19 Apr 23
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
8:07am
8-K
a5kt g09go35jkdab1
18 Apr 23
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
4:45pm
UPLOAD
7dpvo2jn69mj91nw6
13 Apr 23
Letter from SEC
12:00am
8-K
wkikd9tbz4cv nbzjkp1
30 Mar 23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
5:11pm
8-K
32r6q33fo tf9mf
14 Mar 23
Changes in Registrant's Certifying Accountant
12:48pm
8-K
ae0pw9 23
17 Feb 23
OpGen Announces Exercise of All Prefunded Warrants
8:55am
8-K
ulr8ayajzpb w060fvc
23 Jan 23
Other Events
8:00am
8-K
69zxzn5 bo
20 Jan 23
Changes in Registrant's Certifying Accountant
4:32pm
8-K
c3t cfio9nhxptpfj8o
18 Jan 23
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
4:36pm
8-K
ohn6tki
11 Jan 23
OpGen Announces Pricing of $7.5 Million Public Offering
4:37pm
424B3
b3f70ncow26sylhhpj17
11 Jan 23
Prospectus supplement
7:03am
EFFECT
46kv9
9 Jan 23
Notice of effectiveness
12:15am